rivaroxaban우선순위 중간ICSR 검토기타
LITERATURE DETAIL · PMID 42620909
Direct oral anticoagulants in cancer-associated venous thromboembolism: trial robustness and clinical trade-offs.
Direct oral anticoagulants in cancer-associated venous thromboembolism: trial robustness and clinical trade-offs.
- 저자
- Marco Zuin, Cecilia Becattini, Maria Cristina Vedovati, Jean M Connors, Gregory Piazza
- 저널
- Research and practice in thrombosis and haemostasis
- 공개일
- 2026 Jul
- 연구 유형
- 기타
- DOI
- 10.1016/j.rpth.2026.106844
문헌 요약
Although direct oral anticoagulants (DOACs) are often favored over low-molecular-weight heparin for cancer-associated thrombosis, the robustness of trial evidence supporting their use remains uncertain. We evaluated the efficacy, safety, and statistical robustness of DOACs vs dalteparin in patients with cancer-associated venous thromboembolism (VTE). We i…
PV 검토 포인트
개별 증례 가능성과 중대성, 예상성 및 중복 여부를 우선 검토합니다.